Board meeting on November 4, 2026 to approve unaudited results for quarter and half year ended September 30, 2026
Zydus Lifesciences has informed the exchanges that its Board of Directors will meet on Wednesday, November 4, 2026.
By ScoutQuest · · 1 min read
- Board Meeting Date
- Wednesday, November 4, 2026
- Agenda
- approval of unaudited financial results for the quarter and half year ended September 30, 2026
- Trading Window Reopens
- Monday, November 9, 2026 (closed till Friday, November 6, 2026)
What the update says
The company has given notice that a meeting of its Board of Directors will be held on Wednesday, November 4, 2026. The stated purpose, apart from other agenda items, is to consider approval of the unaudited financial results for the quarter and half year ended September 30, 2026.
The notice was issued on October 19, 2026 and signed by the Company Secretary and Compliance Officer.
Trading window
- The trading window for all Directors and Designated Persons remains closed till Friday, November 6, 2026.
- It opens for trading on and from Monday, November 9, 2026.
The trading window is the period when insiders are barred from buying or selling the company's shares, so that people with advance knowledge of results do not trade ahead of the public announcement.
Why investors watch such notices
- The board meeting date tells you when the company's results for the September 2026 quarter and half year are expected to be taken on record.
- Results are the main scheduled update where revenue, profit and margin trends for the period are reported.
- The window reopening date indicates when insiders can resume dealing in the shares.
What to keep in mind
This is a notice of a scheduled board meeting. It does not contain any financial performance figures for the quarter. The results themselves are what will carry the numbers to watch.
Also from Zydus Lifesciences
Zydus Lifesciences Q2 FY27 results on Nov 4, 2026; post-results earnings call same day at 3:30 p.m. IST
24 Oct 2026
Zylidac Bio and Prolific Machines partner to scale Prolific's light-controlled biologics platform to GMP production
21 Oct 2026
Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity
21 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.